

Vidal Health and Serum Institute of India collaborate on HPV Vaccine access

- *First-of-its-kind digital health programme on Vidal Health's platform will offer an end-to-end, convenient and cashless experience, making HPV vaccine more accessible*
- *Collaboration is part of Vidal Health's efforts to provide preventive, digital-first healthcare*

Mumbai/Pune, September 23, 2025: In a step towards preventive and digital-first healthcare, [Vidal Health](#), India's second largest TPA service provider and [Serum Institute of India \(SII\) Pvt. Ltd.](#), part of Cyrus Poonawalla Group, the world's largest vaccine manufacturer, today announced a strategic collaboration to support national efforts in cervical cancer prevention and awareness.

Starting October 1, 2025, Vidal Health's platform will be the first-of-its-kind to offer an end-to-end, convenient and cashless experience for HPV vaccine – from digitally booking a doctor's appointment at a preferred location, to providing consent and receiving certification - all with zero paperwork. The fully managed health programme will provide complete support with timely dosage reminders, adherence monitoring, and efficient network management to ensure continuity of care.

Vidal Health is a 100% subsidiary of [Bajaj Finserv Health](#), a digital platform that integrates the fragmented healthcare delivery ecosystem and offers products and services ranging from preventive to prepaid healthcare, including OPD care and telemedicine.

Sanjiv Bajaj, Chairman & Managing Director, Bajaj Finserv, said, *"Healthcare in India is experiencing a fundamental shift from reactive, post-illness care to preventive care, driven by awareness and transformative initiatives like Ayushman Bharat. At Bajaj Finserv Health, we are shaping this change by building a digital platform that empowers people to stay healthy, with preventive healthcare at its core. Our collaboration with Serum Institute marks a strong*

start to our vaccination programme. By equipping individuals and corporates with digital convenience to manage health proactively, we not only help them cut long-term healthcare costs but also contribute to the nation's sustained well-being."

Adar Poonawalla, Chief Executive Officer, Serum Institute of India, said, *"The HPV vaccine is an important step in preventing cervical cancer, but wider access and awareness are key to its impact. Our collaboration with Vidal Health helps bridge that gap by using technology to deliver the vaccine more efficiently and at scale. This initiative supports our ongoing efforts to make essential vaccines more accessible and improve public health outcomes."*

Neetha Uthaiiah, Whole Time Director, Vidal Healthcare Services Ltd, said, *"The collaboration with Serum Institute is significant in our journey towards making healthcare inclusive and accessible to all. It enables us to deliver transparent and preventive healthcare, in addition to our existing offering of efficient claims processing and a range of wellness programmes. Through this fully managed programme, we aim to reduce hospitalisations and out-of-pocket medical spends, which are high in India, thus optimising the care ecosystem."*

The initiative is significant as it brings together healthcare providers, vaccine manufacturers and national digital platforms such as Aarogya Setu to create a stronger, more connected healthcare ecosystem. It also broadens the gamut of Vidal Health's preventive healthcare offering for individuals — allowing it to expand its health-focused solutions to a broader range of preventive care. Vidal Health's digital platform currently offers doctor consultations, diagnostic tests, health check-ups, wellness programs, and health financing options.

The HPV vaccine will be directly available on Vidal Health's digital platform, ensuring high-quality HPV vaccines with no intermediaries or delays. The platform will enable digital registration, cashless payment and automated tracking of the multi-dose vaccination schedule. Employees at corporates will have the flexibility to get vaccinated at the work premises or at any Vidal Health partner clinic. The entire health programme has been

designed to maximise transparency and adoption across user groups with a pricing that is affordable and inclusive.

About Bajaj Finserv Health & Vidal Health

Bajaj Finserv Health is a leading health-tech company offering preventive, personalised, and partner-led care—including doctor consultations, diagnostics, health financing, and wellness plans. The company empowers organizations and individuals with integrated, cashless, and digital-first solutions to foster a healthier life. Vidal Health is 100% subsidiary of Bajaj Finserv Health, a wholly owned subsidiary of Bajaj Finserv. Bajaj Finserv is one of India's leading and most diversified financial services groups, offering lending, insurance, wealth management, and digital solutions.

To know more, visit [Bajaj Finserv Health](#) [Vidal Health](#)

About Serum Institute of India

Serum Institute of India Pvt. Ltd, part of Cyrus Poonawalla Group is a global leader in vaccine manufacturing, dedicated to providing affordable vaccines worldwide. Present across 170+ countries, including the US, UK, and Europe, SII holds the distinction of being the world's largest vaccine manufacturer. SIIPL's multifunctional production and one-of-the-largest facilities in Hadapsar & Manjari, Pune, with an annual capacity of 4 billion doses, has saved over 30 million lives over the years.

Founded in 1966, SIIPL's primary mission is to produce life-saving immunobiological drugs, with a particular emphasis on affordability and accessibility. Guided by a strong commitment to improving global health, the company has played a pivotal role in reducing the prices of essential vaccines, such as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps, and Rubella. Notably, they are the manufacturers of 'Pneumosiil,' the world's most affordable PCV, 'Cervavac' the first indigenous qHPV vaccine in India, and R21/Matrix-M™, the

second Malaria vaccine to be authorized for use in children in malaria-endemic regions, 'MenFive', the first in the world Pentavalent (ACYWX) Meningococcal Polysaccharide Conjugate Vaccine, approved and WHO-prequalified for use in the pediatric population. Moreover, SIIPL has been at the forefront of the global fight against COVID-19, delivering over 2 billion doses of the COVID-19 vaccine worldwide.

To further expand its global presence and ensure widespread vaccine availability, SII has established Serum Life Sciences Ltd, a subsidiary in the UK and Serum Inc., a subsidiary in the US. Through relentless pursuit of innovation, SII continues to champion the cause of affordable vaccines, making a positive impact on the lives of millions worldwide.

www.seruminstitute.com